Phase 3 N=7 Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep
Alcohol Use Disorder
Primary: Cue-induced Alcohol Cravings Using the Alcohol Urge Questionnaire — -22.67; -23.67 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Substituting Sitting With Standing and Walking in Free-living Conditions Improves Daily Glucose Profile in South Asians
Cardiovascular Risk Factor · Cardiovascular Diseases · Diabetes
Primary: Glycaemia — 98.5; 89.4 mmol/L.16 h
Phase 3 N=277 Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)
Sedation
Primary: The Percentage of Time Sedation Depth is Maintained Within the Target Range, in Absence of Rescue Sedation, as Assessed According to the RASS Scale, in Isoflurane- vs…
Phase 2 N=30 IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC)
Primary: Objective Response Rate (ORR) According to RECIST 1.1 — 4 Participants
Phase 2 N=212 Personalized Trials for Stress Management Against Standard of Care
Stress
Primary: Between-Arm Difference in Change in Ecological Momentary Assessment (EMA) of Stress. — -0.50; -0.31 units on a scale — p=.316
Phase 3 N=302 Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Laboratory Test Abnormalities — 294 Participants
Phase 1 N=40 Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Number of Participants With Cardiac Toxicity, Defined as Reduction in LVEF of >= 10% Compared to Baseline LVEF and EF =< 50% on the Follow-up Scan, Assessed Using MRI…
Phase 3 N=565 Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
Chronic Heart Failure
Primary: Time to Recurrent Non-fatal Decompensated Heart Failure Major Adverse Cardiac Events (HF-MACE) That Occur Prior to the First Terminal Cardiac Event (TCE) — 29.70; 27.53…
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
Phase 2 N=403 Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
Kidney Transplantation
Primary: Percentage of Participants With Composite Efficacy Failure Event (Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death) Over 12 Months Post-transplantation (Cohort…
N/A N=385 Improving the Academic Performance of First-Grade Students With Reading and Math Difficulty
Reading Learning Disability · Math Learning Disability
Primary: Word Reading Fluency-2 (Zumeta et al., 2012) — 10.216; 7.068; 12.349; 7.385 words read correctly — p=.018
N/A N=300 Patient Reported Outcomes With WaveLight LASIK
Myopia
Primary: Patient Satisfaction — 285 Participants
N/A N=133 Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial
Dementia · Cognitive Impairment, Mild · Dementia, Vascular
Primary: Cognitive Impairment — 19; 19 Score on a scale — p=<0.05
Phase 3 N=252 Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Myelofibrosis (MF)
Primary: Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24) — 31.50; 63.20 percentage of participants — p=<0.0001
N/A N=242 Evaluation of Long-term Safety and Performance of PanOptix Trifocal Intraocular Lens (IOL)
Aphakia · Astigmatism · Presbyopia
Primary: Mean Binocular Best Corrected Distance Visual Acuity (BCDVA) — -0.019; -0.012 LogMAR